I'm doing a tribute to the 24 days of Christmas by going over the financial statements of 24 companies that are considered downrange, speculative, and just plain high risk. The legal cannabis industry already has a ton of risk in it - but this stuff - is only for thrill seekers. All opinions are my own, and certainly not a recommendation for or against any of them, or to buy or sell. I've limited myself to 45mins to each, and kept to most recent financial statements and MD&A's. You'll likely know more about the company than me if you're following them. This is only my reactions with a brief commentary about what I see in their latest financial statements. I haven't been consistent in following them all over the past year: some I have, others not. Ah, it's that time of the year again. The smell of chestnuts roasting....the sights of snack tables filled with shortbread & egg nog....of lights and decorations and presents....and that time when the elves revisit the route on their 2017 Dive Bar Pub Crawl. Some of the share prices have been up and down faster than a toddler's mood. Let's take a look, and see who has been 'naughty' or 'nice'. MPX - MPX Bioceutical Price then: $0.40 - Price Now: $0.87 Recently, I toured their Nevada facility, and wrote their financials up here, and you can find the grow op writeup here. Gonna cheat a little this year, and refer to that. KALY - Kalytera Therapeutics, Inc. Price then: $0.29 - Price Now: $0.065
That very expensive Talent Bio pickup wasn't so expensive after all. Bottom fell out of a contingency payment, expected liability turned into income. Presto!
Note 5. Reads like the script from a Mexican soap opera.
If you decide to read Note 5, have a box of tissues, a spreadsheet, a bottle of rum, and a bowl of popcorn handy. You might have need of all four during it. Or maybe just the rum alone.
That $12MM write-down of expected contingent liabilities in Talent landed them $0.01/share in diluted EPS.
Woooo! They're profitable!!!!..???....
First time I've ever seen income derived from G&A.
A true Dive Bar HOF nominee: the 'secured debenture' remains. Note 7.
Best reading yet: Beetlebung Pharma Ltd. (no, I didn't make that up). Find out all about the brand spanking new contingent liabilities in Note 9.
Ugh. Just ugh. As I said last year, pharma is outside of my wheelhouse, as does financials related to them. Anyhow, I still think the financials suck. GLH - Golden Leaf Holdings Price then: $0.28 - Price Now: $0.13
Woot! Announced a merger with Terra Tech! Great fit! Complimentary businesses!
Fast forward 5 weeks, 'merger' off. A one line press release that says nothing else.
My new favorite: 'Unsecured Convertible Subordinated Debenture Units'. They raised $8MM with them.
Which, happened to be closing 2 weeks after the merger announcement.
That retinal burn I got last year was prevented. I invested in a pair of auto-darkening welding glasses. Smart call if you're thinking of reading any of these financials.
Some of these notes shine brighter than a 50 amp arc weld.
Break even business on sales/cogs. Guess that's a positive. They were negative a year ago. At this rate, by 2026, they might have a positive gross margin.
$220k in intangible customer relationships appeared, then disappeared during the period. Yet total customer relationships remain unchanged at $1.512MM. Nyuk-nyuk.
Spoke too soon: the welding glasses reaction time wasn't quick enough to dim the intensity of Note 17. All I can see is spots right now.
Man, life's too short for this shit.
While searching for a reason for the merger cancellation, I came across a Terra Tech comedy sketch. Sadly, there is not even a mention of the merger 'oopsy' on their website. Seriously, if space becomes available in the Crawl, Terra Tech is first in line. As for GLH....well....caveat your fucking emptor. Eye bleach is/was too gentle a term for this outfit's fins. THC Biomed Price then: $0.80 - Price Now: $0.32
G&A and SBC far in the lead of reported operations.
$8MM write-up of warrant liability. Note 10. Yeep.
Of the $1.3MM they paid for the shipper, 1.1MM of it allocated to patents and trademarks.
Lord God above, protect us. Note 10 here could be a contender with some notes in GLH for retinal burn.
Good itemization of G&A. Hey, gotta say something nice. It's xmas after all.
Ok, gonna take that back. Note 15 detail 3 pages (3!) of related party transactions. I've never seen any company in my life require that much.
$5.5MM in loss carry forwards a positive. If they ever make money that is. Which, at a negative margin and a $12MM loss this year.....
Through disclosure, we know that they pay $25 an hour, a $500 xmas bonus, and 250,000 stock options. Which is pretty good. Qualification is that you have to be a close family member of the CEO, and buy $1,400 in product. Well, there's many different fish in the sea. But I do suspect that this isn't a fish, it's just a sea slug. EAT (Nutritional High) Price then: $0.22 - Price Now: $0.18
40% of all assets intangibles/goodwill. Just like an old favorite xmas song we all know the words to.
S/E deficit doubled, now up to $20MM
Gross margin positive. Well then, that is a positive.
Note 23. Holy Hannah. These guys show THC how it's really done in related party transactions. $5MM of the $10MM in total op expenses for the year to related parties. THC? Pffft. Amateurs.
52 pages of statements. Totally fucking merciless. Sociopathic in fact.
I'd need a hyper-cluster of blade servers to calculate the optionality in Note 21 alone. My apologies, I don't have one. Maybe the elves will find one second hand.
Seriously, the complexity of these statements rivals CGC.
Ok. They have stuff littered everywhere, and it doesn't look like any of it is worth anything. Oh, wait, that's what I said last year. Realistically, to get a good handle on this thing, one would need an Act of God. I waited for a little while, but it didn't happen. On to..... RVV - Revive Therapeutics Price then: $0.30 - Price Now: $0.09
Share Capital: deficit of $10MM.
Office expenses: a lean mean $19k. Whoppingly eclipsed by $24k in research costs.
$150k in salaries.
Thankfully, this thing is only 15 pages long. Given it looks like a one person shop operating out of a phone booth, probably also explains it.
Heavy in options, some design around clinical trials. Nothing much else stands out. Again, pharma and value hunting in research ain't something I know much about. The entire assumption in here is that they'll actually put out someday, or get taken out by a larger fish (hopefully for more than the $10MM they've dumped into it). Anyone investing in stuff this downrange, better have your scope sighted in. Or perhaps you know that the FDA's granting of orphan drug status for CBD in the prevention of ischemia and reperfusion injury resulting from solid organ transplantation is just the shot in the arm this company needed. If you do, please keep it to yourself.
Seeing the mentions and feel good messaging coming out about this operation lately piqued my curiosity. Normally, I don’t follow companies that spend on self-promotion around stock price, but one of our mods asked for this, and I wanted to see if there is visible cracks between messaging and reality. There are several, as this outfit has delayed operational announcements, and executed a sale/leaseback to free up cashflow.
Capitalized PP&E greater than goodwill/intangibles. Still 30% of assets.
Despite sales shrinking over the same period a year earlier, margins vastly improving
Lots of hype over the sales distribution network that LTYR brings. Sunnviva paid $8MM for it. Looks like entire value is for licence to distribute.
G&A and SBC $8MM this quarter (yeesh)
Dumped more than a million on forex losses. Given native currency accretion, this logically should be the other way round.
Note 12(e) illustrates a sale/leaseback on buildings and land. Typically, this is a financing vehicle to free up cash flow. Could be considered a desperate move for money, or a strategic focus on operations.
Note 12(g) shows option overhang. Number o/s isn’t massive, but the 8 year tenors are. Extremely rich compensation. The flip side is that mgmt has greater incentive for the longer term. All to the eye of the beholder here.
Note 14(d) explains the forex risk they’re wearing. The delta they report isn’t accurate tho.
Note 15 is one somewhat problematic to me: Related Party transactions. 15(c) is a good example.
Good disclosure on business segments - Note 16. Can’t speak to veracity.
Sales and Marketing expenses relatively low. This will be tested by the new distribution agreement - inasmuch as margin decay and product flow though costs will accrue here.
Capitalizing the build out ($25MM) will end up likely as leasehold improvements on balance sheet. Net $0 to assets.
All in all, it has the feel of a business in build out, and being somewhat behind the capital train’s lead car. Coinciding with the expanded messaging about the company, they’ve just come to market this morning looking for $10MM to provide working capital until expected revenues materialize. 25% of the total amount is being picked up by management. Coincidental? I’m neither ‘fur or ‘agin’ this outfit. Their SBC/G&A is very high for what they’ve achieved, and they’re putting much risk into the California rollout. Looking at their cash and leverage, it puts a lot onto making a splash right away. They’ve put sales numbers to the LTYR potential. With a payback period I eyeball at 3-4yrs. Under their projections, it suggests the buy was good. Tough thing is, it’s all promise. The share price decline they’ve had (and shared with many others) over the past year has stressed access to capital, and much is riding on this distribution deal. The related party transactions are somewhat concerning to me. They’ve made money across management in real estate transactions, construction contracts, legal fees, and consulting gigs. The reader should note this isn’t nefarious on its’ face - it’s not uncommon to have a tight mgmt team rely on each other’s competencies during build, but the intensity is somewhat high (Note 15). For in-sector risk, this one seems to have a lot riding going into a competitive, mature market. Discounts sought by retail for wholesale product a definite threat to margins, and a rough couple of quarters (or slowed realization) of sales expansion will stress cashflow. All I see here is promises, some revenue, & expensive in-house resourcing. I am not close enough (or knowledgeable) about the company and it’s products and the market with which it is heading full steam, into. The valuation I get - including LTYR revenue numbers - comes in at less than the share price value it’s at now, fwiw. The preceding is the opinion of the author, and not intended to be used to buy or sell any equity or derivatives - or anything else for that matter
I'm doing a tribute to the 24 days of Christmas by going over the financial statements of 24 companies that are considered downrange, speculative, and just plain high risk. The legal cannabis industry already has a ton of risk in it - but this stuff - is only for thrill seekers. All opinions are my own, and certainly not a recommendation for or against any of them, or to buy or sell. I've limited myself to 45mins to each, and kept to most recent financial statements You'll likely know more about the company than me if you're following them. This is only my reactions with a brief commentary about what I see in their financial statements. I haven't been consistent in following them all over the past year: some I have, others not. The first one this year.....is here LDS - Lifestyle Delivery Systems Price Then: $0.34 - Price Now: $0.37
They call themselves a pharmaceutical company. Ok. Yet R&D as a percentage of expenses is less than 5% of total. Guessing they discovered what they were looking for.
SBC $1.8MM last quarter.
Revenues have been languishing until this quarter. $600k reported, double the first 6 months of their year.
Gotta say, related party transactions seem to be an emerging theme of this year’s crawl. Note 7.
At the burn rate they have (consulting fees per note 7), they’re gonna have to go back to the well pretty quick.
PP&E increased by $6MM, to $16MM.
Capital structure is a steaming pile (Note 8). Should have a warning statement in front of it before reading.
Speaking of which, immediate vesting of stock options for management is waaay cute.
And unlike most of the year, share price decay is going to be shutting down any fun that could’ve been had.
Almost all o/s warrants exercised. Only 5MM left now.
Bleh. Still looks like a very expensive front office for a million a year in revenue and 50% margin. Leverage is nose bleed inducing, $26MM in accumulated deficit, and no real end in sight. If I was a shareholder - I’d be all over mgmt. As in: ‘when will a business actually emerge here?’. Still looks like an ATM for mgmt. RTI - Radient Technologies Price Then: $1.54 - Price Now: $0.77
Buckets and buckets of cash. $47MM. 2 large raises, one each previous quarter.
Revenue flat yoy. $3.5MM in operating expenses last quarter. Expenses suggest operational build out occurring.
Given quarterly sales of $100k - that build out will need to do something. Sometime. Soon.
SBC is down from $4.2MM to $800k same period. Hmm.
Margin no hell.
Share printer on overdrive (glowing white hot really. Probably could be deployed as a cogen for heat recapture).
Long term debt is cheap.
Share capital in Note 10: an abominable snowman. Really. And since so many of these seem to land in the #10 slot, I’m going to avoid that number on all lotto tickets I buy from here on out.
Take out the bank balance, the market is valuing the business at about $0.50. For 2 years of stagnant revenue and billowing losses...$7MM last 2 quarters alone...meh. They do look to be operationalizing, perhaps that’s the dev cycle this industry business model is within. If that’s the case, I’m looking to see what happens over the next year - and if the spend justifies the returns. Investors should be hoping their sales pipeline doesn’t turn into a TransMountain. TNY - Tinley Beverage Company Price Then: $0.85 - Price Now: $0.46 Funny enough, Tinley came across the radar a few months ago, and the elves took a stab at it. A couple of fans of this outfit took umbrage with their characterization at the time. They still didn’t put up any math though. Nor referenced the financials. I was talking with u/GoBlueCdn the other day on the phone, and in conversation, he said: ‘fundamentals will always bear out.’ I couldn’t agree more. The noise and heat and smoke and knees and elbows of the intra-houday/week/month price moves….will always get throat-punched by solid ops. Never a question of it. It’s simply a function of time. The question of whether fanboys (and their accusations) will still be there when night turns to day….is an answerable one. They usually melt like toilet paper put into water. I stick to financials. If they're rocking it, I'll say so. If they're not......same deal. I haven’t looked at these guys since then. Let’s do it again…..
Cash issues on back burner, they have some now. Given they need it to operate, that’s a good thing.
Intangibles mercifully low (fresh as a spring rain in this crowd).
$30MM deficit in S/E. A pretty large bump under the corner of the rug.
Lost $1.1MM on $52k of sales. Been a year now. And they’ve had the margaritas out now for a quarter. Maybe haven't shown up yet.
Net $100k loss on forex. Sigh. Just like the good ol’ days of last year's Crawl.
Props to them for a SBC and G&A. If this thing looked like an actual business, I suspect it’d be higher.
Shares o/s metastatic. Shares that are issued are seemingly born pregnant.
Godammit. Another Note ’10’. This one is like staring at the sun. Where’d I put those welding glasses…..
CFO is cheap relative to others in c-suite. Bad negotiator, or, value for money? Your choice.
G&A inelegant. See for yourself….Note 15. Honest.
Ok. I could wax poetic for awhile on this, nothing other than incremental at this point really. I don’t have anything against it. I like the idea of drinkables, but I've never tried one. And….I’m woefully ignorant about emulsions and such. If it’s a good product: I’m there. Probably like most people. The reality is that these guys have tripped and slipped and reset several times…and aren’t delivering. Maybe I have expectations that are unreasonable (like the one’s they’ve established in the investor decks?). One way or the other, limping along with no sales will eventually catch up with you. Despite the pitch. Revenues fix almost everything. Onward: iAn - Ianthus Capital Holdings Scratched! Now post merger with MPX - and that I’ve already done that one - means redundancy at this juncture. We’ll skip this, and add a newcomer to the list at the end. Xmas surprise time! CHV - Canada House Wellness Group Inc Price Then: $0.37 - Price Now: $0.13
Lots of cash atm. That’s definitely gonna be needed as we’ll see. Sales Tax rec’ble says they’ve had sales too. They're gonna need every cent.
Liabilities remain as big of yoke as last time. An ox pulling a dull plough through compacted soil is the mental image I get.
$32MM in accumulated deficit in S/E. Plenty of ‘junk in the trunk’.
$1.2MM in revenue. $1.4MM in salaries.
That $1.4MM in salaries is only 38% of total operating expense.
Love the detail in financials. Remember it from last year. All companies can do this. And it’s appreciated.
Interest expenses are from another planet. A very, very big planet.
These guys need a tourniquet. Hemorrhaging from every limb, orifice, window, door, niche and crevice.
Seeing SBC of $1.4MM - in this operational state - C’mon. Seriously. There’s pushing envelopes, and then there’s that.
Added $1.1MM in ‘intellectual property’ - but it’s not itemized. WTF. Did I miss it? Curious if actually omitted. ?
Another Note 10 setting new benchmarks of vulgarity….I got light headed reading it.
This one could have a sign over it’s Note 10 portcullis: ’Abandon all Hope Ye Who Enter Here.’
Interest free loans to a director (when an outfit is in this shape????)
“You are now entering Liquidation City” Population: CHV Home of the ‘cash only’ auction. All purchases must be removed by 5PM or goods and purchase price will be forfeited From doing these guys last year, I recall vividly how much I appreciate good disclosure. With it, there’s not only many more items to divine the entrails of - it also allows one to get a 3D look at an outfit. Often, business dislikes this for obvious reasons (it signals activities/plans/competitive advantages), but also because many people are uncomfortable taking a shower in public. I took my foot off the throttle though after a certain point with these guys - there’s much more to speak to. All of it negative. I went a little overtime on this one, because I like the idea of a patient-centric Canadian producer. But. If these guys last a year….there’s going to have to be capital infusion, and Note 10 will probably expand to the size of a large city’s phone book. It’s looking as proof that c-suite changes don’t change underlying business realities. And these guys need major changes, in far more than management. LIB - Liberty Leaf Holdings Price Then: $0.48 - Price Now: $0.10
not much cash, all they had seems to have gone into ‘facility equipment’.
Since they don’t seem to have a facility (on their books anyhow) that makes sense.
Appears to have pivoted (the elves always chuckle hearing that word) from aspiring producer, to ‘cannabis business accelerator’.
I read this as that they took a couple of runs at getting a grow op up, but got high centred on the meridian of ACMPR licensing delays (Pivot Time!)
Note 8 & 9 cover their ‘investing activities’. But it’s mainly transactional. If they’re ‘building value’ for shareholders, odd way to do it using paper on non-operating assets, and no apparent uplift able to be predicted.
CEO has gotten some help - he’s gone from ‘Chief Cook & Bottle Washer’ to mainly big chair activities.
SBC of a million dwarfs all other income statement spends
60% of assets is their own paper, issued as ‘investment in associate’
$26MM of S/E? Please meet $26MM deficit in S/E. LIB’s capital is ostensibly only paper, and more paper.
If liquidated on hard assets, company would realize $2MM. I didn't have time to look into unconsolidated subs.
The loading of optionality in 2019? Pretty much all struck. Most of management's fruit has been shaken from the tree.
Whoop. Spoke too soon. Still 5MM of $0.17 options left to go. Looks like there’s still a lot of fruit up top yet
Note 19 is all one needs to read on this thing.
This feels like a squatter-aspiring-to-be-taken-out…..shifted to……business-accelerator-ATM-for-mgmt. The businesses they’ve invested in could use a lot of accelerating btw, they’ve picked ones that are like cars rusting in a field. The blockchain outfit has shed half its value since listing, and the late stage applicant’s business(es) appear to be suspended in amber. They’re also connected to some clinical trials, a retail facing outfit, among several others. All paper, all the time. If there’s a business in here outside of a cashlessly fuelled pitch deck (written on lots of paper), I can’t see it. Perhaps something will happen someday. Nothing has in the last 365 of them. Excepting SBC of course. It's been busy there. QCC - Quadron Cannatech Corp Price Then: $0.38 - Price Now: $0.12
Cash and inventory and liabilities and S/E relatively flat.
A/R shows sales throughput
30% margins. G&A lean. SBC exemplary for industry.
SBC might also be low because share price has tanked.
Sales needed. Slower industry ramp has slowed industry need for equipment. Should be stronger year if the underlying operational capacity begins to expand, and demand for units cranks.
Very clean financials. Not much else to say or see.
This one is dead simple in the financial statements. Love love love. Whether they’ll start extracting revenue, is solely a function of their sales channel. As I’ve learned over the past year - everybody (and I mean everybody) - is in the extraction space. Operating in this industry sub-sector is like being in a sardine can without any oil (pun intended). Crowded space indeed. Cashflow is the core of business, and, if QCC can compete and succeed within what is a very competitive landscape - all power to them (and Canadian manufacturing as well). Calling this a ‘challenging environment’ is an understatement. Sales need to begin growing. Another year in the same general state will test market patience, which, is looking like its' already becoming impatient. Disclaimer - I've met Rosy several times now, and have come to respect her very much. I believe she’s a class act: both professionally, and personally. FWIW, full disclosure. I’m gonna go have some egg nog with the elves and compliment them on their behavior. They don't start drinking until after 1PM most days now. That they get out of bed around noon, it's not really saying much. Still, a big improvement over last year.
I'm doing a tribute to the 24 days of Christmas by going over the financial statements of 24 companies that are considered downrange, speculative, and just plain high risk. The legal cannabis industry already has a ton of risk in it - but this stuff - is only for thrill seekers. All opinions are my own, and certainly not a recommendation for or against any of them, or to buy or sell. I've limited myself to 45mins to each, and kept to most recent financial statements You'll likely know more about the company than me if you're following them. This is only my reactions with a brief commentary about what I see in their financial statements. I haven't been consistent in following them all over the past year: some I have, others not. The second one of this year.....is here CMM - Canabo Medical Inc. Scratched! Guess there’s another slot open for a Dive in this year’s Crawl! I did take a run at Aleafia’s financials a few weeks ago though. Their ‘merger’ with Emblem hadn’t yet been announced. Alefia ‘Just Said No’ to cultivation by the looks of it. Best choice for them, at least on the face of it. ISOL - Isodiol International Price Then: $11.50 Price Now: $1.71
Has taken cash and turned it into receivables, inventory, prepaids, and fixed assets. Looking good here.
Except for the $110MM added in goodwill/intangibles. Entrance fee to explore the world of LATAM and vape pens I suppose.
Significant inventory build. 50% margin YTD.
That 50% margin - of $9MM YTD, is supporting $21MM of operating expenses over same period.
Wages and salaries have exploded. As has SBC (which has eclipsed it no less for last period).
As has advertising and promotions. Doesn’t bode well for margin maintenance
Professional fees same. ‘Detonated’ applies as an appropriate adjective as well.
Intangibles/goodwill now 76% of all assets. Up 10%. Less than the rest of G&A is a good thing?
Per Note 19, of the $143MM in these as Canadian assets, they have $0 in revenue attached.
US/UK - far better. Provided that goodwill can be leveraged somewhere…..
Kure Corp eye watering in cost. Hella price to pay for a vape manufacturer. $36MM cash too. Sellers weren’t taking (rolling) paper.
Share price blast radius is notable.
Well then. International operations do attract cost (their G&A is bracing), as does business dev. Especially in Brazil. When a company with a net book value of $2.7MM costs $36MM (takes me back to Canopy buying 2 money losing greenhouses with a net book value of $6MM for $86MM at the time). ISOL’s still shopping too. Round Mountain looks like ISOL tossed them a life preserver. One will have to trust mgmt as to quality/fit of underlying assets. I didn’t detail, it’s only a half million, they bought it for what looks like working capital, I assume it saved them from insolvency. A pretty sweeping and broad horizon is presented by these statements - in a company looking internationally. They’ve got a clean professional presence (I’ve seen them at pretty much every trade show I’ve attended), yet, $12MM in op costs per quarter based on $8MM in sales for same….sheesh. Margin relatively static as well. That needs to improve, and sales need to triple+ to support ops. They lost $6MM per quarter this year, sales modestly up Q over Q. IMH - Invictus MD Price Then: $1.40 Price Now: $0.81
Salaries at $2.5MM, professional fees $1.5MM. To the latter, these have been abating as companies get up and planing. Not here.
Op expenses high, $13MM this quarter. Ouch.
Margin seems erratic. Might be operational stabilization, might be a very dark cloud.
Note 15 explains where their cash came from, along with a 40% increase in shares o/s
Warrant strike prices are all over the map. Relatively modest in options. Despite $2.5MM in SBC this quarter, don’t look like it’s going to be as high for awhile. I’d need more time to confirm that.
Related party transactions…sigh. Compelling business reasons are great. Anything less....more than simply poor optics. Can’t tell either way, in any of these without going deep. Note 16.
Getting a rock star as a front end ain’t cheap. Added $7MM in goodwill, from an $11MM spend. Remainder was expensed in sales and marketing. Well then. Note 10.
Note 11 - ran out of time.
Few things here. While I don’t get the warm and fuzzies from this (what the elves are taking these days apparently does give you that & they swear by it), it looks better than it did last year. I have concerns over sales, margins, and the assets in subs. Wrote one off this year. Only 9 months to find out it’s a mutt? Honestly, this company requires far (far) more time to get a handle on. Will do on website. Needs a full once over to be fair. MDM - Marapharm Ventures (now: LIHT CANNABIS) Price Then: $0.92 Price Now: $0.17
50% of assets goodwill. Full Spectrum indeed. Better be some good gear.
70MM warrants o/s
Shares were issued for 2018 include (clears throat): cash; assets; services; debt; warrant execution; stock options; bond bonus; RSU’s; and even some for the treasury. Whew! Note 14
The 10MM warrants issued at $0.20 look like playing catchup. Share price dump has been….unhelpful in that regard.
Revenues anemic, laying missionary on 30% margins. Blech.
Wrote a gain on a ‘bargain purchase price’ regarding Full Spectrum. Sheesh. After booking the rest as goodwill?
Would show heavy losses if it wasn’t for that $7MM up write.
Good disclosure on commitments (Note 16). And in segmented reporting (Note 17).
Note 21 (subsequent events) is busy. Operationalizing the US.
Sigh. Another that needs more time. Where is Quadron when you need them? Nothing stand out - at least in terms of company differentiation or size. Boring. And leveraged. The Full Spectrum thingy hits their financials like landing an 8 ft fish in a 7 ft boat. I’d need to deconstruct that ‘asset’ to get any strong utility out of this. I’d really want to have a handle on it - and management - if I was to go anywhere near this outfit. Doesn’t look unfairly priced. Unless you ask the people who placed at $0.865, $0.70, and $0.50 during the year. Ugliest thing I see is them issuing shares for $0.38 and $0.04 to retire debts, when the share price was $0.80 and $0.40 respectively. If I was one of those in the private placements, I’d be coming out of my shoes on that (Note 14). Even if it was only $40k. Speaks to quiet desperation at one point. Whether there’s a viable business in here….tune in next time for another episode of ‘Dive Bar Pub Crawl’. As I see it….this would take far too much time for the level of interest I have in it. Unless Full Spectrum is a home run….. ATT - Abattis Biocuetical Corp. Price Then: $0.48 Price Now: $0.08 Man, what a difference a year makes. I’ve largely avoided looking over last years’ Crawl as reference, except to skim for major points. This one remains clear in my memory…it looked like a complete mutt then. Only thing they looked good at was producing press releases. They’re still kicking, as is the rate of news releases/month. They have begun paying a formal IR front end, so maybe this will slow down. Or perhaps speed up. Can’t tell. Ah well, latest fins I can find are somewhat old (Sept release. Amended too :( ). New ones should be due pretty quick.
Sales in first quarter of this year: $237.00. Yep, that’s dollars.
Expenses: $6.9MM same quarter. $3.3MM in consulting fees alone.
Note 13 details the consulting fees. The note is also titled ‘Related Party Transactions’.
Share float increased from 159MM to 406MM YoY. There are no words for this.
Net loss for year end, $24MM on $5,900 in sales. There are fewer than no words for this. Like, an empty set of words.
Well, at least there’s $1.3MM in PP&E. Woot!
And….$51MM in intangibles.
And….$10MM in blockchain, via investment in some sort of clearinghouse to provide liquidity for the crypto-tokens they’ve invented (some sort of Active Health/CanNUMUS spit swap).
* “Token burning will also act as a low‐friction method of returning value to token holders”.* Well, there you go. You can rich, and be frictionless whilst doing so (Note 7).
Gonna stop there. I’ve got a stitch in my side, and a headache. If I ever get my hands on the mug who suggested this one….the elves heads are collectively a ‘bag of cats’, and the little buggers staged a walkout. They’re outside singing Woody Guthrie songs and burning pallets. This totally sucks. As does Abattis’ financials. They offer low friction on tokens perhaps, but any cash put toward this thing will probably have the friction of a canvas bag re-entering the atmosphere. Poof. My personal choice for ‘Dive Bar of the Year’. Curiously, it’s not an easy title to take. IN - Inmed Pharmacuetical Price Then: $1.47 Price Now: $0.37
Plenty of cash. Not much change in assets, or anything else for that matter over the year.
Expenses flat, R&D up, as is SBC. Nothing earth-shaking
Easy to look at from B/S - Income Statement perspective. Loving pharma co’s in this regard.
Active in placements. Steady amount of funds coming in, even if down-raising. Shows interest.
50MM in options and warrants o/s. Share price trajectory has taken a lot of them out of play for the moment.
R&D expenses mainly salaries, nominal amount to patents. In pharma, investors need to have a handle on viability of the research, quality of the management, etc. doing these is kinda fun as the financials are a dream compared to… oh….an ‘Abattis’ let’s say.
TGIF - Friday Night Inc. Price Then: $1.20 Price Now: $0.37 I looked at these guys as recently as July. I also met up with them at MJBizCon in Vegas. I asked for a look at their facility….they never did get back to me. I won a laptop bag and some nice swag at the booth on a business card ‘draw’, it didn’t help getting a tour tho. I really wanted to see it…the financials got me curious in last year’s Crawl, and I strongly get the sense I’m missing something of note in them. Seems an incomplete story tbh. Maybe just some mild indigestion. And….for a region notorious for $70 eights in top shelf, I was also curious why they were recording sub $5 revenue on grams. Got the annuals now….
$6MM in gross margin, $11MM in expenses. Ramping.
Forex and translation (assuming Fx) $1.1MM. A correction, or, an acquisition conversion to native currency.
Modest forecast for sales price per gram ($4.16). I really want to know why their sales price sucks this hard. Outside of scope for the Crawl (time, and, I need an answer from the company. Guys?)
Good disclosure largely, Notes 8, 7, and 11
Writing up forex accretion on goodwill, ptooey.
Still 22MM of in-the-money warrants and options. ~=$4MM live.
Marginal adjustments to cap structure through secured lending. Marginal though.
Related party transactions relatively good compared to peerset.
More good disclosure in segmentation (Note 19).
There’s a reason price softening is lower in this one compared to others - at least they are in production & they have a product suite (at least in their booth at MJBizCon). No retail frontage (?) would explain the shitty sales price. I have somewhat of a soft spot for Canadian business, and I’d hope that relatively early movers would be seeing this start to ramp. As my trip to the US revealed - the US is a hyper-competitive compartmentalized environment. I do believe vertical integration is requisite for a company with this breadth and spend. Gonna sit in on the next call on these guys, and try and get a (the) story. Looks like false starts in build out, and challenges ramping. Sales are growing. They don’t look to be peddling a ’take me out’ story or stance…but….I have blind spots on this one. Because of Abattis, the elves are now wearing balaclavas and carrying home-made gas masks. Told me they are going for a stroll. I gave the RCMP a heads up. Gotta keep up good community relations and all.
FOREX smart ist in erster Linie zur Herstellung von Schildern im Freien vorgesehen, kann aber auch für zahlreiche weitere, typische Display-Anwendungen eingesetzt werden, z.B. im Event-Marketing und in der Schaufenstergestaltung. Es wird vertikal und flach verwendet. Forex smart in schwarz . Forex smart ist ab sofort auch in schwarz lieferbar. Die Lieferung mit einseitiger Schutzfolie ist nun ... FOREX®classic ist die Premium-Platte in der FOREX®-Produktfamilie mit besten mechanischen Eigenschaften und höchster Oberflächengüte.Die feinzellige, homogene Schaumstruktur sowie die gleichmäßig, seidenmatte Oberfläche machen FOREX®classic zum idealen Material für hochwertige und längerfristige Anwendungen im Innen- und Außenbereich. ... Finden Sie Top-Angebote für FOREX® print 8mm weiß PVC - Hartschaumplatte - Werbeschilder - Schaumplatte bei eBay. Kostenlose Lieferung für viele Artikel! FOREX®-CLASSIC ist die leichteste Platte ihrer Art, weist aber trotzdem eine hohe Eigensteifigkeit auf und bleibt auch nach umfangreicher Bearbeitung stabil. FOREX®classic lässt keine Wünsche offen. Mit vielen Dimensionen, Stärken von 1–19 mm und der Eignung für unzählige Anwendungsbereiche ist FOREX®classic längst die massgebende Marke im gesamten Bereich . Anwendungen Forex ... FOREX® print Hartschaumplatten 8 mm Weiß. Premium Hartschaumplatten PVC einseitig foliert. Die wirtschaftliche Lösung für den Druck. Die besonders leichte Hartschaumplatten FOREX® print ist speziell ausgerichtet auf die Anforderungen des Druckbereichs. Die hochweiße und gleichmäßige Oberfläche der Hartschaumplatten bildet speziell beim ... FOREX® Platten PVC Zuschnitt Hartschaumplatten ideal zum Bedrucken Original FOREX® print weiß online kaufen ... 3mm 4mm 5mm 6mm 8mm 10mm: Einsatzgebiete: Innen- und Außenbereich: Gewicht (Dichte): 400-450 kg/m³ bzw. etwa 1,2 kg/m² bei 3 mm Stärke: Baustoffklasse: C-s3, d0 (nach EN 13501-1) Material-Infos: Plattenart: Hartschaumplatte: Recycling-Code: 03: Thermisch: Linearer Ausdehnungs ... Forex® ist einer der bekanntesten Fabrikanten von Polyvinylchlorid (PVC) Plattenmaterial. Unsere Forex® PVC Platten sind sogenannte geschäumte Platten. Sie haben eine harte Oberschicht und einen geschäumten Kern. Dadurch ist die Forex Platte genauso stabil wie eine massive PVC Platte, weist aber nur halb so viel Gewicht auf. Diese Platten eignen sich hervorragend für Werbezwecke und ...
Super Easy London Breakout Strategy (Scalping Forex Market With A Simple System) - Duration: 10:02. The Secret Mindset 67,274 views. 10:02. How To Use The Harmonic Scanner in IML - Duration: 8:47. ... Forex Grundlagen - Pips, Lots und Hebel - Video 1-4 - Duration: 30:17. Gil Paz 62,589 views. 30:17. Hebelwirkung im Trading / Das steckt dahinter - Duration: 8:50. ... 毎週火曜日16:00～16:30 ラジオnikkei第1でも同時放送しています。トレーダー目線を大切に！投資巧者の出演者がトレード手法を指南。マニアックに ... ICmarkets - Best broker for Scalping: https://icmarkets.com/?camp=17903 join IQOPTION NOW!! click here: http://affiliate.iqoption.com/redir/?aff=43932 Facebo... เริ่มต้นเทรดได้ที่ :https://bit.ly/traderathome . https://www.facebook.com/TRADERatHOME/ Live 47 : Ep.14 MM Basic ลืม ... You can buy the FULL version of the robot from the link http://tutshara.com.ua/BS/ ===== DOWNLOAD our new Battle... The broker website, I used in this tutorial is here : https://bit.ly/2yY3lL3 (Roboforex) This is my current broker. Which I find better than most I've used. ... الفوركس / قناه تتحدث عن كل ما هو جديد في عالم الفوركس و أقوي الاستراتيجيات والمؤشرات بالوطن العربي تابعونا ... Le Forex est un panneau en PVC expansé ultraléger et d’application aisée. Le panneau peut-être utilisé dans un grand nombre d’applications et est idéal pour ... #forex #forexlifestyle #forextraderWant to join the A1 Trading Team? See trades taken by our top trading analysts, join our live trading chatroom, and access ou...